Lung Cancer | Exploring the Potential Benefits of Various Adjuvant and Neoadjuvant Therapeutic Approaches for Patients with Localized Non-Small Cell Lung Cancer

Featuring perspectives from Drs Jamie Chaft, Solange Peters, Brendan Stiles and Eric Vallieres, including the following topics: Effect of the recent practice-changing data sets in the adjuvant and neoadjuvant treatment of non-small cell lung carcinoma (NSCLC) (0:00) Case: A woman in her late 60s with Stage IIIA squamous cell carcinoma of the lung and a high level of PD-L1 expression (7:46) Strategies to aid shared decision-making in the adjuvant setting for NSCLC (23:43) Potential role of circulating tumor DNA to detect minimal residual disease in the adjuvant and neoadjuvant settings (28:06) Choosing definitive stereotactic radiosurgery versus sublobar resection in patients with NSCLC (34:53) Case: A woman in her early 80s with PD-L1-negative, Stage IIB lung adenocarcinoma with PIK3CA and TP53 mutations and HER2 amplification (37:24) Experiences with surgery after neoadjuvant systemic therapy in NSCLC (55:38) Case: A woman in her mid-70s with localized pulmonary adenocarcinoma with a MET exon 14 skipping mutation (1:06:23) Clinical outcomes from the Phase III CheckMate 816 trial assessing nivolumab in combination with chemotherapy as neoadjuvant therapy for Stage IB-IIIA NSCLC (1:21:36) Case: A 48-year-old man with a 3.1-cm, Stage IB NSCLC with an EGFR exon 19 deletion (1:35:20) Management of oligometastatic disease with surgery and radiation therapy (1:43:32) Numeracy in adjuvant therapy for NSCLC; estimating the benefit to aid patients in therapeutic decision-making (1:49:11) CME information and select publications